secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-108333
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics completes $600M convertible note offering due 2031
----------------------------------------------------------------------

- Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.
- Effective coupon 1.125%; increased to 1.7308% due to anticipated Swiss withholding tax.
- Initial conversion price ~$76.56 per share, a 45% premium to the $52.80 closing price on March 10, 2026.
- Notes mature March 1, 2031; unregistered, sold to QIBs under Rule 144A; proceeds for general corporate purposes.
- Holders may convert at any time before maturity; company may redeem after March 6, 2029 if stock price condition met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/crsp-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-108333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer